CLOs on the Move

Contrafect

www.contrafect.com

 
ContraFect is a biotechnology company focused on discovering and developing therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. Due to drug-resistant and newly emerging pathogens, hospital acquired infections are currently the fourth leading cause of death in the United States, following heart disease, cancer and stroke. We intend to address drug-resistant infections using our therapeutic product candidates from our lysin and monoclonal antibody platforms to target conserved regions of either bacteria or viruses (regions that are not prone to mutation). ContraFect's initial product candidates include new agents to treat antibiotic-resistant infections such ...
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details
Natalie Bogdanos
General Counsel Profile

Similar Companies

Diagnostic Solutions Laboratory

We are pleased to offer clinicians the first of many advances, the GI-MAP™. The GI-MAP™ (GI-Microbial Assay Plus) stool test utilizes cutting edge, FDA-approved technology to provide a true DNA/PCR based stool analysis which provides actionable informa...

DSM PTG

DSM PTG, Inc is a Berkeley, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Avelas Biosciences

Avelas Biosciences is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Celtic Pharma (Main) US

Celtic Pharma (Main) US is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cullinan Oncology

Cullinan Oncology is focused on investing in and developing a highly diversified portfolio of oncology therapeutics with a unique, cost-efficient business model. Sourced from the Cullinan dry lab as well as external collaborators, Cullinan`s assets are managed by a single, highly experienced team of oncology professionals and drug developers across a lean, capital efficient operating model.